Company: ARTL
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001640334-25-001629
Chunk: 44

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 44
---
, we expect to retain rights to internally develop and commercialize products; however, we may seek collaborations with partners in the biopharmaceutical industry when that strategy serves to maximize value for our stockholders.   Product Candidate Pipeline: |

| Product Candidate                                  | Target Indications                                                                                         | Development Phase | Estimated Market Size                                                                                                               |
| ART27.13 – Synthetic Dual Cannabinoid GPCR Agonist | Anorexia associated with cancer                                                                            | Clinical          | Cancer anorexia cachexia syndrome: >$2 billion                                                                                      |
| ART26.12 – FABP5 inhibitor                         | Chemotherapy Induced Peripheral Neuropathy, Prostate cancer and Breast cancer, pain, and anxiety disorders | Pre-clinical      | CIPN: >$1 billion Prostate cancer: approximately $9 billion Breast cancer: approximately $18 billion PTSD: approximately $7 billion |
| ART12.11 – Synthetic CBD Cocrystal                 | Inflammatory Bowel Disease (IBD), Post-Traumatic Stress Disorder (PTSD), and other potential indications   | Pre-clinical      | IBD: approximately $7 billion PTSD: approximately $7 billion                                                                        |

| 5 |

| Background     The ECS is composed of cannabinoid receptors, endogenous receptor ligands (“endocannabinoids”) and their associated transporter mechanisms, as well as enzymes responsible for the synthesis and degradation of endocannabinoids and has emerged as a considerable target for pharmacotherapy approaches of numerous human diseases. As a widespread modulatory and lipid-signaling system, the ECS plays important roles in the CNS, development, synaptic plasticity, and the response to endogenous and environmental factors.   The modulation of the ECS can be affected by using selective or non-selective agonists, partial agonists, inverse agonists, and antagonists of the cannabinoid receptors, CB1 and CB2. The CB1 receptor is distributed in brain areas associated with motor control, emotional responses, motivated behavior and energy homeostasis. In the periphery, CB1 is ubiquitously expressed in the adipose tissue, pancreas, liver, gastrointestinal tract, skeletal muscles, heart and the reproductive system. The CB2 receptor is mainly expressed in the immune system regulating its functions and is upregulated in response to tissue stress or damage in most cell types. The ECS is therefore involved in pathophysiological conditions in both the central and peripheral tissues.   The actions of endogenous ligands can be enhanced or attenuated by targeting mechanisms that are associated